In addition, Shuttle Pharmaceuticals secured a patent for selective histone deacetylase (HDAC) inhibitors, contributing to its mission to enhance cancer treatments. Moreover, the company faces a ...

While the synergy between Olaparib and the histone deacetylase (HDAC) inhibitor would be of interest ... If this trial shows promising results, the combination of Olaparib with IDH inhibitors maybe a ...

IDH, isocitrate dehydrogenase; TCA, Tricarboxylic acid; HDAC, histone deacetylase; Kla, lactylation. However, the specific mechanisms underlying lactate uptake and utilization by tumor cells have not ...